LivaNova plc (LIVN) Misses Q1 EPS by 10c, Revenues Miss; Updated FY20 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
LivaNova Reports First Quarter 2020 Results
April 29, 2020 6:00 AM EDTLONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020.
For the first quarter of 2020, worldwide sales from continuing operations were $242.4 million, a decrease of 3.4 percent on a reported basis and a decline of 1.8 percent on a constant-currency1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), first quarter 2020 diluted earnings per share from continuing operations were $0.79. First quarter 2020 adjusted diluted earnings per share from continuing operations... More
